Lung cancer study reveals hidden toll of muscle loss during targeted therapy
NCT ID NCT07559526
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the nutrition and body composition of 25 adults with non-small-cell lung cancer who were taking the drug osimertinib. Researchers measured weight, muscle mass, and strength to see how common malnutrition and muscle loss were, and how these affected quality of life. The goal was to gather information, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Complex of Vigo
Vigo, Pontevedra, 36312, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tape to tame Post-Surgery face swelling?
- Can a virtual meadow or a Mind's eye stream calm hospital anxiety?
- Smartwatch could spot nerve damage before it starts
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Could muscle loss predict stroke recovery?